54 results about "Blood triglycerides" patented technology

The invention relates to compounds which are polysufated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and / or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.

The invention discloses a traditional Chinese medicine capsule for treating fatty liver and alcoholic liver. The traditional Chinese medicine capsule is characterized by comprising the following substances in parts by weight of 60-68 parts of hawthorn, 40-46 parts of semen cassia, 18-24 parts of dried tangerine or orange peel, 20-24 parts of rhizoma pinellinae praepa, 30-34 parts of tuckahoe, 40-47 parts of rhizoma alismatis, 40-47 parts of root of red-rooted salvia, 20-26 parts of rheum officinale, 40-44 parts of oriental wormwood, 60-70 parts of astragalus mongholicus, 29-33 parts of polygonum multiflorum, 18-23 parts of honewort, and 19-24 parts of honey-fried licorice root. The traditional Chinese medicine capsule disclosed by the invention is free of toxic and side effects, and has significant curative effects in the aspects of treatment of fatty liver, restoring of liver iconography, improving of the liver function, reducing of serum glutamic pyruvic transaminase and serum total bilirubin, and reducing of blood triglyceride.

Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL / HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and / or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and / or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.

The present invention provides a dietary supplement and methods of using the same to promote body weight reduction and / or loss of body fat in a subject, and for the management of obesity. The supplement can further be used to reduce one or more metabolic parameters in a subject, such as blood glucose levels, blood triglyceride levels, and blood cholesterol levels.

The present invention is related to an extract of Cucurbitaceae family plant or the purified extract isolated therefrom having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The extract of Cucurbitaceae family plant of the present invention showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR α and δ, reducing activity of the gene expression of stearoyl-CoA desaturase, and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.

The object of the present invention is to provide an active substance which has an anti-obesity effect such as a triglyceride lowering activity, a cholesterol lowering activity and the like. The present invention provides a blood triglyceride lowering agent, a cholesterol lowering agent, a body fat storage suppressive agent, an anti-obesity agent and an antilipemic agent, characterized in that each of said agents comprises a cycloartane-type triterpene or glycoside thereof. Moreover, the present invention provides the use of a Black cohosh plant in order to prepare said agents. Further, the present invention provides a beverage, food and quasi-drug comprising said agents.

The invention relates to a food composition with the effects of assisting blood fat reduction, weight loss and liver protection. The food composition is prepared from the following raw materials in parts by weight: 20-25 parts of fructus crataegi, 20-25 parts of lotus leaf, 10-16 parts of radix puerariae, 10-18 parts of green tea, 4-6 parts of fructus lycii, 4-8 parts of poria cocos, 2-4 parts offructus hippophae, 1-3 parts of celery powder, 1-3 parts of folium mori, 1-2 parts of konjac powder, 1 to 3 parts of fructus chaenomelis lagenariae, and 1 to 2 parts of rhizoma polygonati. The prepared food composition can significantly reduce the body weight, fat / body ratio, food utilization rate and blood triglyceride, total cholesterol and low density lipoprotein cholesterol levels in a high fat model rat in the dosage range of each component, also can reduce the liver index, alanine aminotransferase and alkaline phosphatase levels in the high-fat model rat, can significantly increase the relative abundance of bacteroides and decrease the relative abundance of firmicutes, and has the clear effects of assisting blood fat reduction, weight loss, liver protection and intestinal flora improvement.

The present invention relates to Cucurbitaceae plant extracts or purified extracts isolated therefrom having anti-adipogenic and anti-obesity activities, and compositions comprising them. Cucurbitaceae plant extract of the present invention exhibits effective body weight-lowering activity, lowering blood triglyceride and cholesterol content, activating PPARα and δ activity, reducing stearoyl-CoA dehydrogenase gene expression activity and preventing preadipocytes Adipogenesis activity, and no toxicity, therefore, those extracts can be used as medicine or health food for the treatment or prevention of obesity and diseases involving adipogenesis.

The invention belongs to the technical field of traditional Chinese medicine formulas, and relates to a chronic renal failure treatment traditional Chinese medicine composition and a preparation method thereof. The traditional Chinese medicine composition is prepared from 10-15 parts of Radix astragali, 10-15 parts of radix salviae milti orrhizae, 7-12 parts of radix codonopsis, 7-12 parts of radix et rhizoma rhei, 7-12 parts of herba leonuri, 6-10 parts of poria, 6-10 parts of rhizoma atractylodis macrocephalae, 5-8 parts of herba epimedii, 5-8 parts of radix polygoni multiflori and 3-6 partsof rhizoma coptidis. The traditional Chinese medicine composition has effects of effectively reducing blood triglyceride, cholesterol and low-density lipoprotein of patients and improving various serum lipid parameters in different degrees, increasing anemia patient's hemoglobin (Hb) content and improving the patient's anaemic status, improving various hemorheological indexes and improving hypercoagulability and blood circulation, has comprehensive functions of tonifying kidney, spleen and qi, removing turbid materials, clearing damp and dispersing blood stasis, and is an effective composition for treating chronic renal failure.

Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL / HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and / or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and / or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.

The present invention is intended to provide a composition for preventing or improving metabolic syndrome, which is safe and efficiently ingestible. Provided is a composition for reducing blood cholesterol level, improving blood HDL / LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, controlling increase in liver weight, and / or reducing body weight, the composition containing soybean germ protein as an active ingredient. The composition according to the present invention improves blood cholesterol level, triglyceride, and glucose levels thereby contributing to health promotion.

The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes, fatty liver or dyslipidemia or for use in reducing food intake, inducing the feeling of satiety, reducing appetite, reducing body weight, preventing weight gain, reducing body fat, reducing fat formation, reducing blood cholesterol, maintaining normal blood cholesterol levels, reducing blood triglycerides, maintaining normal blood triglyceride levels or increasing insulin sensitivity. The composition can further contain collagen hydrolysate. The composition can be in the form of a pharmaceutical composition, a food, a functional food, a medical food or a food supplement.

The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR alpha and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those compound can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.

The invention provides a vitamin E collagen beverage. The vitamin E collagen beverage comprises the following components of collagen powder, fructose, vitamin C, vitamin E, sodium alginate, sucralose, citric acid, fruity essence and the balance of purified water. The vitamin E collagen beverage disclosed by the invention has the efficacy of beautifying faces, nourishing faces, resisting wrinkles, enabling freckles to be lighter and dispelling freckles on drinking crowds, cannot cause side effects to human bodies after being drunk for a long term, can reduce blood triglyceride and cholesterol, can reduce damage of aluminum to the human bodies, can promote the growth of fingernails and hair, can promote the formation of antibodies and collagen, can maintain immune functions, can promote the synthesis of fat and protein, can maintain the completeness of blood vessels, can participate in the metabolism of phenylalanine, tyrosine and folic acid, can participate in the utilization of ferrum and carbohydrate by human bodies, can resist oxidation, can resist free radicals, and is good in mouth feel; the vitamin E collagen beverage is low in calorie, so that after drinking the vitamin E collagen beverage, people cannot gain weight due to accumulation of calorie; and the vitamin E collagen beverage can promote normal substance metabolism of the human bodies, so that the vitamin E collagen beverage is a healthy beverage.

An agent for suppressing elevation of blood GIP level, an agent for suppressing elevation of blood insulin level, an agent for lowering blood triglyceride level after meal ingestion and an agent for suppressing elevation of blood glucose level, these agents containing potassium polyglutamates as active ingredients.

The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR α and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.

A method for selectively increasing the production of propionate in the gastro-intestinal tract of a mammal. The method includes the step of enterally administering to the mammal a nutritional composition which contains dextran. Increasing the propionate production results in decreased blood cholesterol levels, decreased blood triglyceride levels, decreased very low density lipoprotein levels, increased high density lipoprotein levels, and increased insulin sensitivity.

Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL / HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and / or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and / or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.

This invention provides, a novel polyphenol compound having lipase inhibitory activity derived from tealeaves, a process for the preparation of the compound, and foods and / or beverages and pharmaceutical drugs containing the compound.Particularly, this invention provides a novel dimer compound of formula:obtained by oxidative polymerization of epigallocatechin-3-O-gallate, a main catechin component of oolong tea, with a tealeaf enzyme (polyphenol oxidase), as well as foods and / or beverages and pharmaceutical compositions containing said novel compound which suppress absorption of dietary lipids and suppresses increase of blood triglyceride.

This invention provides, a novel polyphenol compound having lipase inhibitory activity derived from tealeaves, a process for the preparation of the compound, and foods and / or beverages and pharmaceutical drugs containing the compound.Particularly, this invention provides a novel dimer compound of formula:obtained by oxidative polymerization of epigallocatechin-3-O-gallate, a main catechin component of oolong tea, with a tealeaf enzyme (polyphenol oxidase), as well as foods and / or beverages and pharmaceutical compositions containing said novel compound which suppress absorption of dietary lipids and suppresses increase of blood triglyceride.

The present invention provides a prophylactic and therapeutic agent for hyperlipidemia comprising a heterocyclic derivative represented by the following formula [1] or a medically acceptable salt thereof as an active ingredient, and a heterocyclic derivative represented by the formula [1] including The new compound: R 1 -Het-D-E [1] [wherein, R 1 represents an optionally substituted aryl group or an optionally substituted aromatic heterocyclic group. Het represents a divalent aromatic heterocyclic group. D represents an alkylene group, an alkenylene group, an alkynylene group, or the like. E represents carboxylic acid, etc.] The compound of the present invention has the effect of lowering blood triglycerides, lowering LDL-C, and lowering blood sugar. Therefore, it is effective in hyperlipidemia, arteriosclerosis, diabetes, hypertension and It is useful for the prevention or treatment of obesity and the like.

The present invention relates to a composition comprising as an active ingredient a strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity; and to a food composition and a health functional food each comprising the active ingredient. The strain having excellent ability to produce formic acid according to the present invention not only has effects of reducing body weight and inhibiting fat accumulation in organs, but also has activity to effectively lower blood triglyceride and cholesterol levels, and therefore, the composition comprising the strain as an active ingredient can be favorably used as a composition capable of preventing / alleviating or treating obesity or metabolic syndromes caused by obesity. Therefore, the strain having excellent ability to produce formic acid according to the present invention can be favorably used as a material for a medical product or health food.

A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.

The invention relates to an extended release nifedipine agent with sodium alginate as release materials and the components with the weight percentages: nifedipine 10 percent, sodium alginate 30 to 50 percent and the allowance of other medical supplemental materials. By adopting the sodium alginate as the only release materials, the invention has the advantages of strong controllability, stable storage, good efficacy, long control effect and less taking times for patients. As the sodium alginate is natural polysaccharide carbohydrate extracted from kelp, a natural cellulose, the invention not only reduces the side effect of the drugs but also alleviates the absorption of fatty acid and bile salt, thus having the effect of reducing the serum cholesterol, blood triglyceride and blood glucose; at the same time, the invention can prevent the accumulation of harmful metals such as strontium, cadmium and lead in intestinal of bodies and has the advantages of preventing diseases such as hypertension, diabetes mellitus and obesity, preventing sudden pathogenesis and safely spending pathogenesis peak periods.

The invention belongs to the field of animal genetic engineering and genetic modification, and in particular relates to the application of Abcg4 gene in constructing an animal model with two-way changes in obesity degree. The use specifically refers to constructing an animal model by knocking out the Abcg4 gene in an animal, or inhibiting the expression of the Abcg4 gene. The degree of obesity in the animal model is dependent on sex, as compared to wild-type littermates of the same sex, females become obese and blood triglyceride levels decrease, while males become lean and blood triglyceride levels increase. The model of the invention can be used to study obesity and related diseases, and can be used to screen out more effective and targeted drugs for treating obesity or treating elevated plasma triglycerides.

The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula Ä1Ü or a pharmaceutically acceptable salt thereof: R<1>-Het-D-E wherein: R<1> is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula Ä1Ü above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

There is provided a pharmaceutical composition for treatment or prevention of a neurodegenerative disease, comprising an RXR agonist as an active ingredient, which is a compound represented by formula (1) or (2). The pharmaceutical composition is effective in treatment or prevention of neurodegenerative diseases such as dementia, Parkinson's disease and multiple sclerosis with reducing side effects such as enlargement of the liver and elevation of blood triglyceride level. In these formulas, A represents CMe2, N-methyl, N-ethyl or N-isopropyl; X represents N, CH or C—CF3; Y and Z represent N or CH; R1 represents methyl, hydroxy, methoxy or ethoxy; R2 represents H, methyl or ethyl; B represents NR3 or CHR3; R3 represents alkyl; and R4 represents H, halogen, alkyl, alkenyl, aryl, alkynyl, alkoxy or acyl.